FDA / ICH reference questions

**Fast regulation search** Searched the local FDA/ICH regulation database and found **6 matching sources** for: _What essential documents are required before a trial begins?_ --- ## Q&A 1: What are Essential Documents per ICH GCP Section 8? **Category:** Documentation **Source:** `ICH GCP Section 8` **Answer:** Documents permitting evaluation of trial conduct and data quality. Filed in TMF: Before Phase (protocol, IB, ICF, IRB approval, 1572), During Phase (CRFs, source docs, AE reports), After Phase (datasets, audit certificates). --- ## Source 2: 8.0 — Essential Documents for the Conduct of a Clinical Trial **Reference:** `ICH GCP E6(R2) Section 8.0` **Category:** Documentation **Match Score:** 0.7817 8.0 Essential documents are those documents that individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor and monitor with the standards of GCP and with all applicable regulatory requirements. Essential documents include: Before Trial Phase: Signed protocol and amendments, sample CRF, IB, signed consent form, IRB/IEC approval, regulatory authorization, CVs of investigators, financial disclosure, insurance statement, signed agreement between sponsor and investigator. During Trial Phase: CRFs, signed informed consent forms, source documents, subject screening log, subject identification code list, subject enrolment log, serious adverse event reports. After Trial Phase: Trial data archival, audit certificates, final trial report. --- ## Q&A 3: What is the Trial Master File (TMF)? **Category:** Documentation **Source:** `ICH GCP Section 8` **Answer:** Complete set of essential documents evaluating trial conduct and data quality. Demonstrates GCP compliance. Per ICH GCP Section 8. --- ## Source 4: FDA Guidance — Critical to Quality Factors **Reference:** `FDA Guidance: Risk-Based Monitoring (2019)` **Category:** Monitoring **Match Score:** 0.5457 FDA recommends that sponsors identify Critical-to-Quality (CtQ) factors early in trial design. CtQ factors are attributes of a clinical trial that are essential to ensure: (a) Protection of human subjects, (b) Reliability of trial results, (c) Decision-making based on credible data. CtQ factors help prioritize monitoring activities. The identification of CtQ factors should focus on: (1) Processes that are most likely to impact subject safety and data integrity. (2) Data that are critical for the trial's primary and key secondary endpoints. (3) Areas where errors are most likely to occur and where errors would have the greatest impact. --- ## Source 5: CRA Practice — Source Document Verification (SDV) Procedure **Reference:** `ICH GCP E6(R2) Section 5.18.4 + Industry Best Practice` **Category:** SDV **Match Score:** 0.5217 SDV is the process of comparing source documents against CRF/EDC entries to verify accuracy. PRACTICAL PROCEDURE: BEFORE SDV: 1. Request source documents in advance (schedule with site coordinator) 2. Review previous visit reports and open queries 3. Identify subjects and data points requiring 100% verification 4. Check regulatory binders and essential documents DURING SDV: 1. Compare each data point in source vs. CRF systematically 2. Verify: subject ID, visit date, AE/SAE entries, concomitant meds, protocol procedures 3. Check ICF dates (must be signed BEFORE any study procedure) 4. Verify eligibility criteria match enrollment records 5. Check query resolution: corrections were made properly 6. Document each subject reviewed in monitoring log 7. For EDC: check audit trail for late entries or back-dating AFTER SDV: 1. Document all discrepancies as queries 2. Summary of SDV in monitoring visit report 3. Follow up on unresolved items WHAT TO VERIFY PER ICH GCP 5.18.4: - Subjects' rights and well-being are protected - Reported data are accurate, complete, and verifiable from source documents - Site conducts trial according to protocol and GCP - Protocol deviations are identified and reported --- ## Source 6: CRA Practice — Site Close-Out Visit (SCO) Procedure **Reference:** `ICH GCP E6(R2) Sections 4.13, 5.20, 8.0 + Industry Best Practice` **Category:** Monitoring **Match Score:** 0.4662 PRACTICAL SITE CLOSE-OUT PROCEDURE per ICH GCP: BEFORE THE VISIT: 1. Confirm all data queries are resolved 2. Verify final SDV is complete 3. Request final IP accountability report 4. Confirm all AEs/SAEs are followed up 5. Schedule with PI and coordinator AT THE VISIT: 1. FINAL SDV: Complete any remaining source data verification 2. IP RECONCILIATION: Final count of IP dispensed, returned, destroyed 3. RETURN IP: Collect and document all unused IP for return or destruction 4. RECORDS RETENTION: Confirm site will retain records per regulatory requirements (typically 2 years after IND/IDE termination or as per local regulations) 5. TMF: Verify trial master file is complete or identify gaps 6. SUBJECT TRANSITION: Document plan for ongoing subject care after trial ends 7. FINANCIAL: Finalize any outstanding payments 8. FINAL MEETING: Review close-out summary with PI — PI acknowledges in writing 9. NOTIFICATIONS: Verify IRB has been notified of trial completion/termination 10. ESSENTIAL DOCUMENTS: Collect final documents, archive per sponsor requirements DOCUMENTATION: - Site close-out visit report - Final IP reconciliation log - Record retention agreement signed by PI - PI acknowledgment of close-out - Final monitoring visit log entry COMMON ISSUES: - Unresolved queries (must be resolved before close-out) - Missing essential documents - IP not fully reconciled - PI unaware of record retention obligations --- *Tip: Try rephrasing your question for more targeted matches.*